普洛药业(000739.SZ)：头孢泊肟酯片获得药品补充申请批准通知书

Core Viewpoint - Prolo Pharmaceutical (000739.SZ) announced that its wholly-owned subsidiary, Zhejiang Prolo Jutai Pharmaceutical Co., Ltd., received the approval notice for the supplementary application of Cefoperazone Ester Tablets from the National Medical Products Administration [1] Group 1: Product Information - Cefoperazone Ester is an oral broad-spectrum third-generation cephalosporin that exerts antibacterial effects after being hydrolyzed by non-specific esterases in the body [1] - The drug is effective against both Gram-positive and Gram-negative bacteria [1] - It is indicated for infections caused by sensitive bacteria, including upper respiratory tract infections, lower respiratory tract infections, uncomplicated urinary tract infections, uncomplicated skin and soft tissue infections, acute uncomplicated gonococcal urethritis, cervicitis, and perianal infections caused by Neisseria gonorrhoeae [1]